MEW network self-management program characteristics and lessons learned through the RE-AIM framework.

Adults Behaviors Epilepsy Implementation research RE-AIM Self-management

Journal

Epilepsy & behavior : E&B
ISSN: 1525-5069
Titre abrégé: Epilepsy Behav
Pays: United States
ID NLM: 100892858

Informations de publication

Date de publication:
03 2023
Historique:
received: 06 07 2022
revised: 23 12 2022
accepted: 24 01 2023
pubmed: 23 2 2023
medline: 11 3 2023
entrez: 22 2 2023
Statut: ppublish

Résumé

The promotion of evidence-based self-management support for people living with chronic conditions such as epilepsy is a public health priority. Epilepsy self-management encompasses three general areas: (1) treatment management, (2) seizure management, and (3) lifestyle management. Interventions focusing on self-management have increased quality of life and adherence to treatment. This study assesses and synthesizes the Managing Epilepsy Well Network (MEWN) program implementation experiences using the RE-AIM framework. This research informs the quality and rigor of MEWN program dissemination and implementation efforts to assess whether these programs are being implemented and their scalability. The study data were derived from a MEWN Self-management Program Survey conducted with currently active MEWN researchers through an online survey and review of program publications and archival documents. Survey data were obtained from either the principal investigator or study team for the UPLIFT, HOBSCOTCH, SMART, MINDSET, TIME, and PACES programs. The survey questionnaire included 6 sections consisting of 68 questions and focused on the RE-AIM dimensions and respondent characteristics. The RE-AIM dimensions included: (1) Reach, (2) Effectiveness, (3) Adoption (number of and type of adopting sites), (4) Implementation (retention rate, barriers to implementation), and (5) Maintenance. Across the MEWN programs, participation (44-120 individuals) and delivery methods (community, clinic, or asynchronous; group or individual) ranged with most programs predominantly reaching White or African American participants. Common program outcome measures included clinical outcomes (e.g., depression, quality of life, seizure frequency) and indicators of self-management behaviors (e.g., problem-solving; self-efficacy). Initial efficacy trials suggested programs were effective in changing some of their targeted outcomes (effectiveness). Most programs were implemented in clinical settings and several programs are being replicated or adapted to different geographical (e.g., urban, rural, suburban) or demographic (e.g., race, age) settings (adoption). Program delivery methods involved a mixture of program staff, peer educators, and researchers. Implementation enabling factors included partnerships with local epilepsy organizations and the inclusion of peer educators. Retention rates for all programs averaged 83.6%. Internal barriers included recruitment and lack of sufficient resources for participants. External barriers included clinical staff buy-in, staffing, and insufficient funding for support staff. Despite uncertain funding, all programs offered next steps to sustain their initiatives such as packaging their programs, initiating adoption with regional organizations, and supporting organizational readiness (maintenance). Dissemination efforts included partnering with other organizations, provision of training and technical assistance, and partnering with national organizations on grant opportunities to scale up existing programs. These data showcase the impact of the MEWN self-management interventions on health and quality of life. These programs are employing training, readiness assessment, technical assistance, and development of partnerships to increase program scalability. Finally, program adaptations are being conducted to expand the interventions to other populations to address health inequalities. The lessons learned are critical for other interventions attempting to increase the translation of their programs to other settings.

Identifiants

pubmed: 36804716
pii: S1525-5050(23)00029-X
doi: 10.1016/j.yebeh.2023.109111
pii:
doi:

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

109111

Subventions

Organisme : NCCDPHP CDC HHS
ID : U48 DP006398
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U48 DP006411
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U48 DP006377
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U48 DP006413
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U48 DP005042
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U48 DP006389
Pays : United States

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Martha Sajatovic declares these other disclosures. Research grants within past 3 years: Nuromate, Otsuka, International Society for Bipolar Disorders (ISBD), National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Patient-Centered Outcomes Research Institute (PCORI). Consultant in the past year: Alkermes, Otsuka, Sunovion, Janssen, Lundbeck, Teva, Clinical Education Alliance, Health Analytics. Royalties in the past year: Springer Press, Johns Hopkins University Press, Oxford Press, UpToDate. Compensation for preparation of/participation in CME activities past year: American Physician’s Institute (CMEtoGo, Psychopharmacology Institute, Novus, American Epilepsy Society, American Society of Clinical Psychopharmacology, American Academy of Child and Adolescent Psychiatry, Neurocrine. Other authors disclose no competing interest for this study.

Auteurs

Cam Escoffery (C)

Emory University, Rollins School of Public Health, 1518 Clifton Road, Atlanta, GA 30322, United States. Electronic address: cescoff@emory.edu.

Archna Patel (A)

Emory University, Rollins School of Public Health, 1518 Clifton Road, Atlanta, GA 30322, United States.

Jerik Leung (J)

Emory University, Rollins School of Public Health, 1518 Clifton Road, Atlanta, GA 30322, United States.

Molly Anderson (M)

Emory University, Rollins School of Public Health, 1518 Clifton Road, Atlanta, GA 30322, United States.

Robin McGee (R)

Emory University, Rollins School of Public Health, 1518 Clifton Road, Atlanta, GA 30322, United States.

Martha Sajatovic (M)

Case Western Reserve University, 10900 Euclid Ave, Cleveland, OH 44106, United States.

Erica K Johnson (EK)

University of Washington, Health Promotion Research Center, 1107 NE 45(th) St #200, Seattle, WA 98105, United States.

Barbara Jobst (B)

Dartmouth-Hitchcock Medical Center, 1 Medical Center Dr, Lebanon, NH 03766, United States.

Elaine T Kiriakopoulos (ET)

Dartmouth-Hitchcock Medical Center, 1 Medical Center Dr, Lebanon, NH 03766, United States.

Ross Shegog (R)

University of Texas School of Public Health, 7000 Fannin St #1200, Houston, TX 77030, United States.

Robert Fraser (R)

University of Washington, Health Promotion Research Center, 1107 NE 45(th) St #200, Seattle, WA 98105, United States.

Rakale C Quarells (RC)

Morehouse School of Medicine, 720 Westview Dr SW, Atlanta, GA 30310, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH